ArticleRheumatology (Oxford, England)2025
Type I interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Prevalence of Anemia and Diagnostic Usefulness of Ferritin and Hepcidin in Antiphospholipid Syndrome and Systemic Lupus Erythematosus Patients.Diseases (Basel, Switzerland) · 2026Article
- [Why C-reactive protein is (usually) not high in SLE].Zeitschrift fur Rheumatologie · 2026Review
- Mechanisms and clinical research progress of IL-6-mediated crosstalk between the alveolar microenvironment and the immune system in patients with severe pneumonia undergoing mechanical ventilation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo fully understand why C-reactive protein (CRP) is usually only mildly elevated in active systemic lupus erythematosus (SLE), although interleukin-6 (IL-6) is increased, but is high in SLE patients with bacterial infections.
methodsSera and peripheral blood mononuclear cells (PBMCs) of SLE patients and healthy individuals were investigated. IL-6 and soluble IL-6 receptor (sIL-6R) were measured by ELISA. Membrane IL-6 receptor-α (CD126), gp130 (CD130) and signal transducer and activator of transcription 3 (STAT3) phosphorylation after IL-6 stimulation were analysed by flow cytometry. PBMCs and HepG2 liver cells were stimulated with various cytokines, and IL-6 receptor shedding was determined by immunoprecipitation and western blotting of supernatants. HEK-293 T cells were transfected with wild type CD126 or a shedding-resistant mutant, and soluble sIL-6R was measured following cytokine stimulation.
resultsWhile sIL-6R and IL-6 were increased with SLE activity, CD126 positive lymphocytes were decreased in SLE. IL-6 plus IFNα decreased CD126 on lymphocytes, but increased sIL-6R in their supernatant, detected by immunoprecipitation and western blotting. IL-6 plus IFNα on HepG2 liver cells resulted in a similar sIL-6R increase. Increased supernatant sIL-6R was seen in HEK-293 T cells transfected with wild type CD126, but not those transfected with the shedding-resistant mutant. STAT3 phosphorylation upon IL-6 stimulation was reduced.
conclusionThe combination of IL-6 and type I IFN induces shedding of CD126 to sIL-6R, shifting IL-6 signalling to trans-signalling. In situations of IL-6 excess over sIL-6R only, IL-6 or IL-6-sIL-6R complexes reach the liver and increase CRP. These findings not only explain the discrepancy in SLE, but also have implications for severe viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.